Interstitial cystitis/bladder pain syndrome is a chronic condition characterized by bladder pain, pressure, or discomfort associated with urinary frequency, urgency, and nocturia, lasting ≥6 weeks, and is a diagnosis of exclusion after ruling out infection, malignancy, and other confusable disorders. [1-3] The 2022 AUA guidelines no longer use a tiered treatment approach; instead, treatment is categorized into behavioral/non-pharmacologic, oral medications, intravesical instillations, procedures, and major surgery, individualized to each patient. [1]
The following figure illustrates the three recognized IC/BPS phenotypes — Hunner lesion, widespread pain (nociceptive), and low bladder capacity — which have distinct pathophysiologies and treatment implications:
1. History
- Pain characterization: Location (suprapubic, pelvic, urethral), quality (pressure, burning, discomfort), relationship to bladder filling (classic worsening with filling, relief with voiding) [1-2]
- Voiding symptoms: Frequency (often >8 voids/day), urgency, nocturia, low voided volumes [1]
- Timing and triggers: Flare-up pattern — common triggers include specific foods/beverages, stress, sexual intercourse, exercise, menstruation, tight clothing, prolonged sitting [1][5]
- Associated symptoms: Dyspareunia, dysuria, ejaculatory pain (men), relationship of pain to menstrual cycle (women) [1]
- Important negatives: Absence of hematuria, fever, vaginal/penile discharge, weight loss, prior pelvic radiation, history of bladder cancer
2. Alarm Features
- Gross or microscopic hematuria → requires workup for urothelial malignancy [1-2]
- New-onset symptoms in older patients with tobacco exposure → bladder cancer risk [1]
- Fever, pyuria, or positive urine culture → suggests UTI rather than IC/BPS
- Rapid symptom onset (<6 weeks) → less likely IC/BPS; consider acute infection, stone, or foreign body
- Incomplete bladder emptying or urinary retention (PVR >100 mL) → suggests outlet obstruction or neurogenic bladder [2]
- History of pelvic radiation, prior bladder surgery, or vaginal mesh → warrants specialist referral [2]
- Neurological deficits (saddle anesthesia, lower extremity weakness) → cauda equina syndrome
3. Medications
- Relevant contributors: Cyclophosphamide (hemorrhagic cystitis), ketamine (ketamine cystitis), certain chemotherapeutics
- Common treatments (no hierarchy per AUA): [1-2]
- Amitriptyline 25–75 mg nightly — evidence for symptom improvement; common anticholinergic side effects [6]
- Hydroxyzine 25–75 mg nightly — may benefit patients with allergy history [2]
- Cimetidine 400 mg BID [1]
- Gabapentinoids — improvement in refractory pain, well tolerated [2]
- Pentosan polysulfate (Elmiron) 100 mg TID — only FDA-approved oral therapy; conflicting efficacy data [2][7]
- NSAIDs, phenazopyridine — for symptomatic/flare management [2]
- Vaginal estrogen — in postmenopausal women to address genitourinary syndrome of menopause [2]
- Pentosan polysulfate caution: Pigmentary maculopathy is a dose-dependent, potentially irreversible adverse effect. Baseline ophthalmologic exam required; retinal exam within 6 months of initiation and periodically thereafter. Symptoms include difficulty reading, impaired dark adaptation, blurred vision [1][7-8]
- Cyclosporine A — reserved for refractory cases under specialist care; serious adverse events possible [2][6]
- Contraindicated/avoid: Kegel exercises (pelvic floor strengthening) may worsen symptoms in patients with pelvic floor hypertonicity [1]
4. Diet
- ~90% of IC/BPS patients report food/beverage sensitivities that exacerbate symptoms [9-10]
- Common dietary triggers: [9-11]
- Caffeine (coffee, tea, energy drinks)
- Alcohol
- Carbonated beverages
- Citrus fruits and juices
- Tomatoes and tomato products
- Spicy foods
- Artificial sweeteners
- Vitamin C supplements
- Soy products, high-potassium foods
- Dietary management approach: Systematic elimination diet followed by gradual reintroduction to identify individual triggers [1][9]
- Hydration: Adjust fluid intake to achieve desired urine concentration — both excessive concentration and excessive volume can worsen symptoms [1-2]
- Symptom-soothing agents: Calcium glycerophosphate and sodium bicarbonate may improve symptoms [9]
- Intensive systematic dietary manipulation has shown sustained symptom improvement at 3 months and 1 year [12]
5. Review of Systems
- GU: Frequency, urgency, nocturia, dysuria, dyspareunia, hematuria, vaginal discharge, menstrual irregularities
- GI: Abdominal pain, bloating, diarrhea/constipation (IBS co-occurs in 30–75%) [13-14]
- MSK: Diffuse myalgias, joint pain (fibromyalgia co-occurs in ~18%) [14]
- Neuro: Fatigue, sleep disturbance (chronic fatigue syndrome ~10%) [14]
- Psych: Depression, anxiety, catastrophizing, sleep disturbance [13][15]
- Derm/Allergy: Allergic history (may predict hydroxyzine response)
6. Collateral History and Family History
- Familial aggregation: Strong heritable interrelationships exist among IC/BPS, fibromyalgia, IBS, chronic fatigue syndrome, major depressive disorder, and panic disorder across first-, second-, and third-degree relatives [16]
- Childhood conditions: History of childhood urological anomalies (HR 2.49), GI disorders, and psychiatric disorders increase adult IC risk [17]
- Social context: Impact on work productivity, sexual function, relationships, and emotional well-being should be assessed [18-19]
- Trauma history: Adverse childhood experiences, abuse, and PTSD are associated with chronic pelvic pain conditions [13][15]
7. Risk Factors
- Female sex (4:1 female-to-male ratio) [2]
- Comorbid nociplastic pain syndromes: IBS, fibromyalgia, chronic fatigue syndrome, migraines, vulvodynia [14-15]
- Psychiatric comorbidities: Depression, anxiety, PTSD — significantly more prevalent in IC/BPS patients [15][20]
- Autoimmune/rheumatologic conditions: Higher odds of rheumatoid arthritis, SLE, ankylosing spondylitis [20]
- Exogenous female hormones [21]
- History of recurrent UTIs (may represent prodromal IC/BPS) [21]
- Two phenotypic patterns: Prodrome phenotype (onset in early 20s, systemic pain) vs. non-prodrome phenotype (onset in early 40s, bladder-centric) [21]
8. Differential Diagnosis
- Cannot-miss diagnoses:
- Bladder cancer — especially in older patients, smokers, chemical exposure, hematuria [1-2]
- Bladder stones / intravesical foreign body [1]
- Complicated UTI / chronic infection [1]
- Common mimics:
- Overactive bladder (OAB) — urgency/frequency WITHOUT pain (pain distinguishes IC/BPS from OAB) [22]
- Recurrent UTI — positive cultures; may coexist [22]
- Endometriosis — cyclic pain, dysmenorrhea; co-occurs in ~48% of IC/BPS patients [13][22]
- Vulvodynia — vulvar-localized pain rather than bladder pain [22]
- Pelvic floor myalgia / levator ani syndrome — trigger points, pain with palpation [13]
- Genitourinary syndrome of menopause — vaginal atrophy, dysuria in postmenopausal women [2]
- Chronic prostatitis/CPPS (men) [2]
- Urethral diverticulum [23]
- Ketamine cystitis — history of ketamine use
- IC/BPS is misdiagnosed in up to 43% of cases, most commonly confused with OAB or non-bladder-centric pain [24]
9. Past Medical History
- Prior episodes of bladder pain or "recurrent UTIs" with negative cultures
- Previous pelvic surgeries (hysterectomy, mesh placement, bladder surgery)
- History of pelvic radiation
- Chronic pain conditions (fibromyalgia, IBS, chronic fatigue, migraines, vulvodynia)
- Autoimmune diseases
- Psychiatric history (depression, anxiety, PTSD)
- Medication history — especially prior pentosan polysulfate use and duration
10. Physical Exam
- Vitals: Typically normal; abnormal vitals suggest alternative diagnosis
- Abdominal exam: Suprapubic tenderness on palpation
- Pelvic exam (women): Assess for vaginal atrophy, pelvic organ prolapse, levator hypertonicity, trigger points, bladder base tenderness on anterior vaginal wall palpation [2]
- Genital/prostate exam (men): Assess for prostatitis, epididymitis
- Brief neurological exam: Lower extremity strength, sensation, reflexes, perineal sensation — to rule out occult neurologic pathology [1]
- Post-void residual: Bladder scan or catheterization to rule out retention (>100 mL abnormal) [2]
11. Lab Studies
- Urinalysis and urine culture — required in all patients; must be negative to support IC/BPS diagnosis. Culture may be indicated even with negative UA [1-2]
- Urine cytology — if concern for malignancy (hematuria, smoking history, older age)
- CBC, BMP — if systemic illness suspected
- STI testing — if sexually active and symptoms overlap
- PSA — in men if prostatitis or malignancy suspected
- Potassium sensitivity test — no longer recommended (lacks specificity, causes significant pain) [2]
12. Imaging
- First-line: Not routinely required for uncomplicated presentations [1]
- Bladder/kidney ultrasound or CT urography — when alternative diagnoses suspected (stones, masses, structural abnormalities) [2]
- Pelvic ultrasound/MRI — if endometriosis, pelvic mass, or structural abnormality suspected
- Gold standard: No imaging modality is diagnostic for IC/BPS; diagnosis is clinical
- Imaging unnecessary when presentation is classic and confusable diseases excluded
13. Special Tests
- Voiding diary (minimum 1-day log) — establishes low-volume, high-frequency voiding pattern characteristic of IC/BPS [1]
- Validated symptom scores: [1-2]
- O'Leary-Sant ICSI/ICPI (Interstitial Cystitis Symptom/Problem Index)
- Genitourinary Pain Index (GUPI)
- Visual Analog Scale (VAS) for pain
- Cystoscopy — not required for diagnosis in uncomplicated cases; indicated when diagnosis is in doubt, hematuria present, or to identify Hunner lesions (the only consistent diagnostic cystoscopic finding) [1-2]
- Hydrodistension under anesthesia — can serve as both diagnostic (staging bladder capacity, identifying Hunner lesions) and therapeutic [1]
- Urodynamics — not routinely recommended; consider if outlet obstruction or poor detrusor contractility suspected [1]
14. ECG
- Not routinely indicated for IC/BPS
- Consider if initiating amitriptyline (QT prolongation risk) or if cardiac symptoms present
- Baseline ECG recommended before tricyclic antidepressant use, especially in patients >40 years or with cardiac risk factors
15. Assessment
IC/BPS is a chronic, relapsing-remitting condition with significant impact on quality of life, sexual function, work productivity, and emotional health. [2][18] It is a diagnosis of exclusion requiring ≥6 weeks of symptoms with negative urine cultures. [1] The condition is increasingly recognized as heterogeneous, with at least three phenotypes (Hunner lesion, widespread pain/nociceptive, and low bladder capacity) that may require different treatment approaches. [4] Severity can be stratified by symptom scores (ICSI/ICPI), voiding frequency, pain intensity, and impact on daily function. Comorbid conditions (IBS, fibromyalgia, depression) are common and worsen outcomes as they accumulate. [14]
16. Treatment Plan
Treatment is multimodal, individualized, and no longer follows a rigid stepwise algorithm per the 2022 AUA guidelines. [1]
Behavioral/Non-Pharmacologic (First-Line): [1-2]
- Patient education on disease course and flare management
- Bladder training, timed voiding, urge suppression techniques
- Dietary modification with elimination diet approach
- Fluid management (optimize urine concentration)
- Pelvic floor physical therapy — associated with symptomatic improvement
- Stress management: CBT, yoga, mindfulness-based stress reduction
- Heat/cold application to bladder or perineum
- Avoid tight clothing, constipation, high-impact pelvic floor exercises
Oral Pharmacotherapy: [1-2]
- Amitriptyline 25–75 mg nightly
- Hydroxyzine 25–75 mg nightly
- Cimetidine 400 mg BID
- Gabapentin/pregabalin for refractory pain
- Pentosan polysulfate 100 mg TID (with ophthalmologic monitoring)
- NSAIDs, phenazopyridine for flare management
- Vaginal estrogen in postmenopausal women
Intravesical Instillations: [1]
- DMSO — dwell time 15–20 minutes; often in "cocktail" with heparin, lidocaine, steroid
- Heparin — GAG layer restoration
- Lidocaine ± alkalinization — short-term symptom relief; enhanced with heparin or PPS
- Hyaluronic acid / chondroitin sulfate — GAG layer restoration [25-26]
Procedures: [1]
- Cystoscopy with hydrodistension under anesthesia
- Hunner lesion fulguration/resection (if lesions identified)
- Sacral neuromodulation
- Botulinum toxin A injection (intradetrusor)
Major Surgery — reserved for refractory cases: augmentation cystoplasty, urinary diversion ± cystectomy
17. Disposition
- Outpatient management is appropriate for the vast majority of IC/BPS presentations
- Admission criteria: Rarely indicated; consider for intractable pain unresponsive to outpatient management, inability to void, or concern for alternative surgical diagnosis
- Observation: Patients presenting to the ED with severe flares may benefit from IV hydration, parenteral analgesia, and brief observation
- Specialist referral triggers: [2]
- Inadequate response to behavioral/medical management
- Hematuria (gross or microscopic) without UTI
- History of urothelial malignancy or pelvic radiation
- Prior bladder surgery or vaginal mesh
- Structural abnormalities (prolapse, diverticulum)
- Suspected endometriosis → gynecology
- Chronic prostatitis → urology
- Incomplete bladder emptying or retention
18. Follow Up / Return Precautions
- Follow-up timing: 4–6 weeks after initiating treatment to reassess symptom scores and treatment response [1-2]
- Ongoing monitoring: Serial ICSI/ICPI or VAS scores at each visit; ophthalmologic exams if on pentosan polysulfate [1][7]
- Return precautions — seek immediate care for:
- New hematuria (gross blood in urine)
- Fever or signs of infection
- Inability to urinate or severe urinary retention
- Intractable pain unresponsive to home management
- New neurological symptoms (leg weakness, numbness, bowel/bladder incontinence)
- Patient counseling:
- IC/BPS is a chronic condition with a relapsing-remitting course; complete cure is uncommon, but symptoms can be significantly managed
- Flares are expected — identify and avoid personal triggers
- Support groups (e.g., Interstitial Cystitis Association) can improve coping and quality of life [27]
- Expected recovery: gradual improvement over weeks to months with multimodal therapy; treatment adjustments are common
References
1. Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome. — Clemens JQ, Erickson DR, Varela NP, Lai HH. The Journal of Urology. 2022.
2. Bladder Pain Syndrome: Rapid Evidence Review. — Roepcke F, Jones AE, Falk KN. American Family Physician. 2026.
3. Joint Terminology Report: Terminology Standardization for Female Bladder Pain Syndrome. — Developed by the Joint Writing Group of the International Urogynecological Association and the American Urogynecologic Society. International Urogynecology Journal. 2025.
4. A Review of the Etiopathology of Phenotypes in Interstitial Cystitis/Bladder Pain Syndrome. — Sandberg ML, Santurri L, Klumpp D, et al. Neurourology and Urodynamics. 2026.
5. Management of Symptom Flares and Patient-Reported Flare Triggers in Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)-Findings From One Site of the MAPP Research Network. — Lai HH, Vetter J, Song J, et al. Urology. 2019.
6. Efficacy and Safety Comparison of Pharmacotherapies for Interstitial Cystitis and Bladder Pain Syndrome: A Systematic Review and Bayesian Network Meta-Analysis. — Di XP, Luo DY, Jin X, et al. International Urogynecology Journal. 2021.
7. FDA Drug Label. — Updated date: 2024-09-18. Food and Drug Administration.
8. Pentosan Polysulfate Maculopathy: Clinical Considerations, Pathobiology, and Causality. — Hall BP, Shiromani S, Vanderbeek BL, et al. Progress in Retinal and Eye Research. 2025.
9. Diet and Its Role in Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) and Comorbid Conditions. — Friedlander JI, Shorter B, Moldwin RM. BJU International. 2012.
10. Effect of Comestibles on Symptoms of Interstitial Cystitis. — Shorter B, Lesser M, Moldwin RM, Kushner L. The Journal of Urology. 2007.
11. Food Sensitivities in a Diverse Nationwide Cohort of Veterans With Interstitial Cystitis/Bladder Pain Syndrome. — Jarman A, Janes JL, Shorter B, et al. The Journal of Urology. 2023.
12. Clinical Efficacy of 1-Year Intensive Systematic Dietary Manipulation as Complementary and Alternative Medicine Therapies on Female Patients With Interstitial Cystitis/Bladder Pain Syndrome. — Oh-Oka H. Urology. 2017.
13. Chronic Pelvic Pain in Women: A Review. — Lamvu G, Carrillo J, Ouyang C, Rapkin A. The Journal of the American Medical Association. 2021.
14. Interstitial Cystitis/Painful Bladder Syndrome and Associated Medical Conditions With an Emphasis on Irritable Bowel Syndrome, Fibromyalgia and Chronic Fatigue Syndrome. — Nickel JC, Tripp DA, Pontari M, et al. The Journal of Urology. 2010.
15. Comorbidities in a Nationwide, Heterogenous Population of Veterans With Interstitial Cystitis/Bladder Pain Syndrome. — Laden BF, Bresee C, De Hoedt A, et al. Urology. 2021.
16. The Multi-Generational Familial Aggregation of Interstitial Cystitis, Other Chronic Nociplastic Pain Disorders, Depression, and Panic Disorder. — Allen-Brady K, Fyer AJ, Weissman M. Psychological Medicine. 2023.
17. Comparative Risk of Developing Interstitial Cystitis With Childhood Gastrointestinal, Urological, Autoimmune, or Psychiatric Disorders. — Alipour-Vaezi M, McNamara RS, Rukstalis MR, et al. Neurourology and Urodynamics. 2025.
18. Interventions for Treating People With Symptoms of Bladder Pain Syndrome: A Network Meta-Analysis. — Imamura M, Scott NW, Wallace SA, et al. The Cochrane Database of Systematic Reviews. 2020.
19. Coping With Interstitial Cystitis/Bladder Pain Syndrome. — Sutherland S, Grace Kelly A, McKernan LC, et al. Neurourology and Urodynamics. 2024.
20. Comorbidities of Bladder Pain Syndrome/Interstitial Cystitis: A Population-Based Study. — Keller JJ, Chen YK, Lin HC. BJU International. 2012.
21. Prodrome and Non-Prodrome Phenotypes of Bladder Pain Syndrome/Interstitial Cystitis. — Warren JW, Jian N, Gallicchio L, Wu D, Clauw DJ. Urology. 2018.
22. Symptoms of Interstitial Cystitis, Painful Bladder Syndrome and Similar Diseases in Women: A Systematic Review. — Bogart LM, Berry SH, Clemens JQ. The Journal of Urology. 2007.
23. Chronic Pelvic Pain: ACOG Practice Bulletin, Number 218. — Committee on Practice Bulletins—Gynecology Obstetrics and Gynecology. 2020.
24. The misdiagnosis of interstitial cystitis/bladder pain syndrome in a VA population. — Skove SL, Howard LE, Senechal J, et al. Neurourology and Urodynamics. 2019.
25. Impact of Intravesical Chondroitin Sulfate Instillation on Sexual Function in Women With Interstitial Cystitis/Bladder Pain Syndrome. — Uçar M, Topcuoğlu M, Akkoç A, et al. International Urogynecology Journal. 2026.
26. Recurrence After Postoperative Intravesical Instillation Therapy in Hunner Type Interstitial Cystitis. — Ko KJ, Koo MJ, Bang S, et al. Scientific Reports. 2023.
27. Interstitial Cystitis: Urgency and Frequency Syndrome. — Metts JF. American Family Physician. 2001.